layoffs
Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce
The company is shifting its focus to developing EGFR and BRAF inhibitors and believes cutting staff will extend its cash runway into Q3 2024.
Silverback Discontinues Targeted Oncology Programs, Reduces Staff
The company terminated development of two antibody-drug conjugates due to lackluster anti-tumor activity and cytokine-related adverse events.
Ziopharm Oncology Restructures to Focus on Advancing Autologous T-Cell Receptor Therapies
The firm has cut over half of its positions and plans to use its cash to generate data for its TCR-T Library program and construct in-house manufacturing facilities.